Skip to content
OpenCapital
Get started

MoonLake Immunotherapeutics MLTX Cash Provided by (Used in) Financing Activity, Including Discontinued Operation

Cash Provided by (Used in) Financing Activity, Including Discontinued Operation at other companies

Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
$40.6M—

Other financials

Income statement

See full
Operating income-$70.0M-47.5%
Net income-$69.7M-74.5%
EPS (diluted)-$0.98-55.6%

Balance sheet

See full
Cash & equivalents$298.5M+9.9%
Total debt$100.8M+33.3%
Total equity$254.0M-37.7%
Total assets$400.4M-21.7%

Cash flow

See full
Operating cash flow-$66.3M-73.8%
CapEx--100%
Free cash flow-$66.3M-73.6%

Valuation

See full
Market cap$1.49B-45.9%
Enterprise value$1.29B-50.0%

Returns & leverage

See full
Return on equity-77.7%-221pp
Debt / equity0.4×+0.2×
Current ratio8.6×-12.5×

Where this comes from

Reported directly by MoonLake Immunotherapeutics in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The official record: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about MoonLake Immunotherapeutics's cash provided by (used in) financing activity, including discontinued operation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MoonLake Immunotherapeutics's cash provided by (used in) financing activity, including discontinued operation?
MoonLake Immunotherapeutics (MLTX) reported cash provided by (used in) financing activity, including discontinued operation of $30.64M in Q1 2026.
How has MoonLake Immunotherapeutics's cash provided by (used in) financing activity, including discontinued operation changed year-over-year?
MoonLake Immunotherapeutics's cash provided by (used in) financing activity, including discontinued operation decreased by 58.1% year-over-year, from $73.12M to $30.64M.
What is the long-term trend for MoonLake Immunotherapeutics's cash provided by (used in) financing activity, including discontinued operation?
Over 4 years (2021 to 2025), MoonLake Immunotherapeutics's cash provided by (used in) financing activity, including discontinued operation has grown at a 19.5% compound annual growth rate (CAGR), from $71.53M to $146M.
What does cash provided by (used in) financing activity, including discontinued operation mean?
This metric measures the net cash flow between the company and its capital providers, including proceeds from debt or equity issuance and payments for dividends or share repurchases. It highlights how the company finances its operations and returns value to shareholders.